CD155, also referred to as the poliovirus receptor, functions as a shared ligand for both activating (DNAM-1) and inhibitory receptors (TIGIT, CD96), with its expression significantly upregulated across multiple tumor types, including ovarian cancer (23). Here, PVR is linked to neoplasm.